A drug containing a lab-produced ‘antibody’ reduces hospital admission or death from Covid-19 by 85 per cent, its maker GlaxoSmithKline (GSK) has announced.

VIR-7813, created by GSK and Vir Biotechnology, is a new treatment for those with mild to moderate illness. However, a trial using the drug on very sick patients was halted last week due to a lack of benefit.

It contains monoclonal antibodies — laboratory-produced molecules that mimic human antibodies.

Due to its success, the global phase 3 clinical trial was stopped early with plans to immediately seek an emergency use authorisation in the United States and approval in other countries, including potentially the UK.

Initial analysis of the trials was based on data from 583 patients at risk of hospital admission. It found that hospital admissions or death were reduced by 85 per cent.

The drug works by blocking the virus from healthy cells and clearing infected cells, and is designed to be given as a single intravenous (IV) infusion.

VIR-7831 has also been found to be effective against the most common current Covid-19 variants, including the Kent, South African and Brazilian variants, in a separate study.

Dr Hal Barron, chief scientific officer at GSK, said: “We are pleased that this unique monoclonal antibody was able to bring such a profound benefit to patients.

Image Credit:   GSK

Post by Amanda Scott, NA CEO.  Follow her on twitter @tantriclens

Thanks to Heinz V. Hoenen.  Follow him on twitter: @HeinzVHoenen

Read the Article

News

New, better coronavirus rapid test

Researchers at the Paul Scherrer Institute PSI and the University of Basel have developed a rapid test for COVID-19. Its novel functional principle promises reliable and quantifiable results concerning a patient's COVID-19 disease and [...]

Nanocomposite Hydrogel Improves Bone Repair Treatment

Innovative researchers have investigated the potential of incorporating a gelatin methacryloyl hydrogel functionalized with synthetic nanoclay laponite to improve the delivery of osteoblast derived extracellular vesicles for increased bone repair. This research has been [...]

Applying Nanoemulsions to the Food Sector

Nanoemulsions are a relatively new technology that has found significant use for delivering functional chemicals such as micronutrients, flavorings, bioactive molecules, and antimicrobial agents into food and beverage products. This article focuses on applying [...]